Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation

Reid-Nicholson, Michelle; Kavuri, Sravankumar; Üstün, Celalettin; Crawford, Jennifer L.; Nayak-Kapoor, Asha; Ramalingam, Preetha

doi:10.1002/cncr.23794

Cited by 20 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunophenotype of all 3 cell lines was identical to the original tumor. They were positive for CD138 and negative for other lineage markers, CD3, 5,10,14,16,19,20,22,23,38,45,56 ( Fig. 2C and data not shown) on flow cytometry.…”

Section: Establishment and Characterization Of Cell Linesmentioning

confidence: 88%

“…It is clinically aggressive with a median survival of 6 months, with most patients dying within 1 year of the onset of disease; however, it has been suggested that the addition of highly active antiretroviral therapy (HAART) to chemotherapy is capable of significantly improving the prognosis in HIV-positive patients (2,5,6). Epstein-Barr virus (EBV) or Kaposi sarcoma-associated human herpesvirus 8 (HHV8) have been proposed to play a relevant role in the pathogenesis of this disease, although the involvement of the latter remains controversial (7)(8)(9)(10). Altogether, the pathogenesis of plasmablastic lymphoma is yet largely unknown due to the lack of disease model, cell lines, and diseasespecific chromosome or gene aberrations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Loss of p16 Expression and Upregulation of MDR-1 as Genetic Events Resulting from Two Novel Chromosomal Translocations Found in a Plasmablastic Lymphoma of the Uterus

Matsuki

Miyakawa

Asakawa

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To establish cell lines from the patient with plasmablastic lymphoma, who was immunologically competent including negative human immunodeficiency virus (HIV) serology, and analyze the unique chromosomal translocations seen in the cell lines in order to unveil the pathogenesis of this tumor, which had no evidence of Epstein-Barr virus involvement.Experimental Design: Establishment of the cell lines was attempted by inoculating the patient's lymph node biopsy specimen subcutaneously to immunodeficient mice. Comparative genomic hybridization (CGH) array and FISH analysis were performed to identify breakpoints of the two chromosomal translocations. Of the 4 candidate genes identified by FISH analysis to be involved in the translocations, reverse transcription-PCR, Western blot, flow cytometry, and proliferation assay were performed to identify the exact genes involved.Results: Analysis of the cell lines identified loss of p16 at the protein level by chromosomal translocation of t(9;13) and upregulation of MDR-1 by t(4;7). The cell lines expressing MDR-1 acquired resistance to chemotherapeutic agents such as cisplatin and doxorubicin, but not bortezomib. Expression of B lymphoid lineage marker genes of these cell lines was negative for paired box 5 (Pax5) or PR domain containing 1, with ZNF domain (PRDM1), but was positive for X-box binding protein 1 (Xbp1).Conclusions: We established three novel cell lines of plasmablastic lymphoma. Characterization of the unique chromosomal translocation identified loss of p16 and upregulation of MDR-1 at protein level. Expression of Xbp1(s), which is involved in the maturation of plasma cells, corresponded to the plasmablastic appearance of the tumor. These cell lines may be a useful tool to understand the pathophysiology of the disease and to develop novel treatment strategies.

show abstract

Section: Establishment and Characterization Of Cell Linesmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Identification of Loss of p16 Expression and Upregulation of MDR-1 as Genetic Events Resulting from Two Novel Chromosomal Translocations Found in a Plasmablastic Lymphoma of the Uterus

Matsuki

Miyakawa

Asakawa

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Bu lenfomanın özelliği immunohistokimyasal olarak B hücre göstergelerinin (CD20, CD45 gibi) zayıf pozitif veya negatif, buna karşılık plazma hücre göstergelerinin (CD38, CD138, VS38c gibi) ve EBV antijeninin sıklıkla pozitif olmasıdır. 2,4,5,[12][13][14][15][16][17] PBL'nin sıklıkla genç yaşlarda (ortalama 39 yaş), erkek cinsiyette (%79), oral kavitede (%66) görüldüğü ve yine sıklıkla EBV ile ilişkili olduğu (%74) bildirilmiştir. (4) bölge, omentum, testis, Kİ ve santral sinir sistemi (SSS) tutulumları değişik yayınlarda bildirilmiş-tir.…”

Section: Discussionunclassified

Oral Plasmablastic Lymphoma in a Case with HIV Infection

Ural¹,

Kaptan²,

Türker³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Ö ÖZ ZE ET T Plazmablastik lenfoma (PBL) nadir görülen bir malignitedir ve en sık HIV (human immunodeficiency virus) ile enfekte olgularda ve yine sıklıkla oral kavitede saptanmaktadır. İlk kez 1997 yılında tanımlanmıştır. Diffüz büyük B-hücreli lenfomanın farklı bir alttipi olarak tarif edilmiştir. Son yıllarda sıklıkla oral kavite dışında da rapor edilmiştir. Gastrointestinal sistem ve deri, oral kavite dışında en sık tutulan organlardır. Plazmablastik lenfoma genellikle tipik B-hücre göstergelerinde (örnek olarak CD20) negatiflik, CD38, CD138 ve VS38c gibi plazma hücre göstergelerinde pozitiflik içeren karekteristik bir immunofenotip gösterir. Biz, bu makalede 44 yaşında, oral kavitede 30x30 mm boyutlarında kitle, akciğer tüberkülozu ve beyinde sol talamik bölgede 18x30 mm boyutlarında kitle lezyonu saptanan HIV ile enfekte bir erkek olgu sunduk. Oral kavitedeki lezyonun histopatolojik incelemesi PBL ile uyumlu idi. Neoplastik hücreler CD20 negatif bulundu. Hematoksilen eozin boyasında çok katlı yassı epitel altında plazmasitoid özellikte, iri eozinofilik nükleuslu, bazıları nükleolus içeren mitoz aktif neoplastik lenfoid infiltrasyon izlendi. Kemik iliği biyopsisinde non-Hodgkin lenfoma (NHL) tutulumu tespit edildi. Olguya HIV enfeksiyonu açısından HAART (Highly active antiretroviral therapy) tedavisi olarak stavudin + lamivudin + lopinavir/ritonavir; akciğer tüberkülozu tedavisi için dörtlü anti-tüberküloz tedavi olarak izoniazid + etambutol + rifampisin/streptomisin + morfoziamid; PBL için kemoterapi olarak siklofosfamid + doksorubisin + onkovin + prednizon (CHOP) ve radyoterapi verildi. Tedaviye rağmen olgu 7,5 ay izlendikten sonra kaybedildi. Erken tanı ve uygun tedavi olguların yaşam sürelerini uzatabileceği için HIV enfekte olguların nadir görülen maligniteler açısından taranmasına dikkati çekmek amacıyla ve ülkemizdeki ilk olgu olması nedeniyle bu olgu bildirilmiştir.A An na ah ht ta ar r K Ke el li im me el le er r: : HIV enfeksiyonları; lenfoma, Aids ile ilişkili; lenfoma, büyük B-hücreli, yaygın A AB BS ST TR RA AC CT T Plasmablastic lymphoma (PBL) is a rarely seen malignant lesion and it is most commonly detected in HIV (Human-immunodeficiency virus)-infected subjects predominantly in the oral cavity. It was first described in 1997. It has been recognized as a distinct entity, as a subtype of diffuse large B-cell lymphoma. Recently, PBL presentation has been reported frequently outside the oral cavity. Gastrointestinal tract and skin were the most commonly involved extra-oral organ systems. Plasmablastic lymphoma usually displays a characteristic immunophenotype that includes negativity for typical B-cell markers (eg, CD20), and positivity for plasma cell markers such as CD38, CD138 and VS38c. In this report, we described a case of PBL in a 44-year-old HIV infected male patient who presented with an expanding 30x30 mm oral lesion, pulmonary tuberculosis and an 18x30 mm cerebral left thalamic lesion. Histopathological evaluation of the lesion in oral cavity was consistent with PBL. The neoplastic c...

show abstract

“…There tumor cells are of medium to large size. [33][34][35] The most common cytologic features noted on fine needle aspiration are hypercellularity, plasmablastic cells, single cell necrosis, and background necrosis (Fig. 7).…”

Section: Primary Effusion Lymphomamentioning

confidence: 99%

“…7). 35 In rendering a diagnosis by relying on immunophenotype can be challenging, because the tumor cells may be CD45À and CD20À. The neoplastic cells express plasma cellassociated markers such as MUM-1 or CD138 and have a high proliferation fraction.…”

Section: Primary Effusion Lymphomamentioning

confidence: 99%

Extranodal lymphomas: Review of clinicopathologic and cytologic features

Siddiqui

Pitelka

Gattuso

2009

Diagnostic Cytopathology

View full text Add to dashboard Cite

Extranodal lymphomas can be challenging for a practicing cytopathologist, especially in the fine needle aspiration clinic setting. These lymphomas can vary in type from one extranodal site to another. A variety of these lymphomas have very specific clinicopathologic features. They also may be associated with underlying autoimmune diseases, immunodeficiency syndromes, infection, or be noted in unique ethnic communities. This article reviews some of the commonly encountered lymphomas in extranodal sites with an emphasis on clinicopathologic and cytologic features.

show abstract

Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation

Cited by 20 publications

References 22 publications

Identification of Loss of p16 Expression and Upregulation of MDR-1 as Genetic Events Resulting from Two Novel Chromosomal Translocations Found in a Plasmablastic Lymphoma of the Uterus

Identification of Loss of p16 Expression and Upregulation of MDR-1 as Genetic Events Resulting from Two Novel Chromosomal Translocations Found in a Plasmablastic Lymphoma of the Uterus

Oral Plasmablastic Lymphoma in a Case with HIV Infection

Extranodal lymphomas: Review of clinicopathologic and cytologic features

Contact Info

Product

Resources

About